Lemborexant - Purdue Pharma

Drug Profile

Lemborexant - Purdue Pharma

Alternative Names: E-2006; LEM 10; LEM 5

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Inc
  • Developer Eisai Inc; Purdue Pharma
  • Class Cyclopropanes; Hypnosedatives; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Insomnia
  • Phase II Circadian rhythm sleep disorders

Most Recent Events

  • 05 Feb 2018 Eisai in collaboration with Purdue Pharma initiates enrolment in a phase I drug-drug interaction trial (In volunteers) in USA (NCT03451110)
  • 30 Jan 2018 Eisai completes the phase III SUNRISE 1 trial in Insomnia (In the elderly, In adults) in United Kingdom, Canada, Spain, Italy, Germany and USA (PO) (NCT02783729)
  • 29 Jan 2018 Eisai and Purdue Pharma initiate a phase I pharmacokinetics trial in subjects with normal or impaired renal function in USA (PO) (NCT03443063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top